C Difficile Infection

A gastroenterologist, Dr. Bincy Abraham, provides an overview of C. difficile infection (CDI) in patients with inflammatory bowel disease (IBD).

Drs. Lodise and Feuerstadt discuss educational opportunities to combat and reduce C. difficile infection (CDI).

Dr. Chopra shares multipronged approach to reducing C. difficile infection (CDI) and the role of antimicrobial stewardship.

Drs. Abraham, Chopra and Feuerstadt discuss importance of timely referral and diagnostic methods to discern C. difficile infection (CDI).

Drs Lodise and Feuerstadt discuss risk factors for C. difficile infection (CDI).

A gastroenterologist, Dr. Paul Feuerstadt, provides an overview of C. difficile infection (CDI) and vegetative and spore phases of CDI.

Contamination was 11.5% on floors, 7.9% on infusion chairs, and 3.8% on equipment.

The majority of cases were mild to moderate in severity.

EoE expert Dr. Marc Rothenberg says it's a relief to know that the FDA has finally approved a drug for EoE.

RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.

With limitations on fidaxomicin at their facility, a hospital looked at vancomycin usage to determine if they needed to align with the new IDSA/SHEA CDI treatment guideline.

Christian Lillis of the Peggy Lillis Foundation for C. Diff Education & Advocacy discusses the need for greater industry-organization support and drug development.

A South Korea in-hospital assessment found that approximately half of all ordered CDI tests did not meet recommendation standards.

Developing research into the specific alterations of dysbiosis and diseases like arthritis suggest possibly novel pathways to therapy development.

New data suggest prediction of SARS-CoV-2 and bacterial co-infection or superinfection could be provided for hospitalized patients.

New-onset diarrhea is common among inpatients and residents of long-term care facilities.

The most common diagnoses were found to be non-malignant, including upper gastrointestinal problems in men and urinary tract infections in women.

A study shows the Visceral Sensitivity Index could help identify anxiety and health-related quality of life burden in patients with IBS or IBD.

These signatures were also related to unfavorable stress responses related to gastrointestinal symptoms.

The new guidance restructures how study designers should look at trial population, efficacy benchmarks, and safety in clinical trials involving drug development.

Propolis is a resinous give product collected by honeybees from varied petals and plant buds sources.

A combination of first-line management consisting of validation, explanation, and a positive diagnosis, non-pharmacological treatments, and pharmacological treatment should be considered for pediatric patients with IBS or functional abdominal pain disorders.

Antibiotic and proton pump inhibitor use was also associated with an increased risk of C difficile infection.

Pediatric patients with CDI had a higher number of previous-day hospital admissions, hospitalizations, and total hospital admissions.

There were key aspects that differed in the gut microbiota between patients with major depressive disorder and the healthy control group.

methylnaltrexone is more effective, less costly, and can even keep some patients out of the hospital after being treated for opioid-induced constipation in the emergency department.

There are several emerging treatments for C difficile infections.

A large proportions of patients with C difficile infections do not respond to metronidazole.

New research shows diarrhea did not increase overall mortality for hospitalized patients.

C Difficile infections decreased in VA healthcare facilities during the COVID-19 pandemic.